British Columbia Cancer Agency, Department of Pathology and Experimental Therapeutics, Vancouver, BC, Canada.
Leuk Lymphoma. 2010 Aug;51 Suppl 1:11-9. doi: 10.3109/10428194.2010.500046.
There has recently been a rapid expansion in research aimed at identifying biomarkers that could improve the prognosis for patients with various subtypes of malignant lymphoma. Genomic and genetic studies have led to the identification of biological and clinical subgroups of diffuse large B-cell lymphomas with distinct underlying molecular features, divergent activation of oncogenetic pathways, and clinical course. Molecular studies of follicular lymphoma have suggested complex interactions between malignant cells and the surrounding immunological network that could affect disease progression. Moreover, the inflammatory cells of Hodgkin lymphoma have been shown to produce a complex network of cytokines and chemokines that provide a permissive microenvironment for tumor growth. Research into specific biomarkers and signaling pathways of malignant lymphomas might therefore result in the identification of novel targets for future therapeutic strategies. As gene expression profiling techniques are not yet feasible in the clinical laboratory, studies have aimed to translate the findings into more widely applicable techniques that might allow this research to be applied to routine clinical practice. This review focuses on recent advances in translational and clinical research on biomarkers in malignant lymphomas.
近年来，旨在确定生物标志物以改善各种恶性淋巴瘤亚型患者预后的研究迅速扩展。基因组和遗传学研究已经确定了弥漫性大 B 细胞淋巴瘤的生物学和临床亚群，这些亚群具有不同的潜在分子特征、不同的癌基因途径激活和临床病程。滤泡性淋巴瘤的分子研究表明，恶性细胞与周围免疫网络之间存在复杂的相互作用，可能影响疾病进展。此外，霍奇金淋巴瘤的炎症细胞已被证明能产生细胞因子和趋化因子的复杂网络，为肿瘤生长提供了一个许可的微环境。因此，对恶性淋巴瘤的特定生物标志物和信号通路的研究可能会确定未来治疗策略的新靶点。由于基因表达谱分析技术在临床实验室中尚不可行，因此研究旨在将这些发现转化为更广泛适用的技术，以使这项研究能够应用于常规临床实践。本综述重点介绍了恶性淋巴瘤中生物标志物转化和临床研究的最新进展。
